Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekPharmaVoice ↗
GLP-1s will fuel the industry's growth in the coming years if outside forces don't get in the way.…
The WeekFiercePharma ↗
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView's corporate reputatio…
The WeekFierceBiotech ↗
Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on…
The WeekBriefing
Tzield gains accelerated approval to delay insulin decline in children 8–17 with recently diagnosed Stage 3 ty…
The WeekPharmaceutical Technology ↗
Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Phar…
The WeekBioPharma Dive ↗
Elsewhere, Otsuka's kidney drug hit the goal of a confirmatory trial and Vertex's CRISPR sickle cell drug secu…
The WeekBioPharma Dive ↗
The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney …
The WeekBioPharma Dive ↗
A group of coming decisions could provide important insights into how flexible the agency is willing to be und…
The WeekPharmaVoice ↗
Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its o…
The WeekFiercePharma ↗
Tara Sparks was just days away from starting her new job at Novo Nordisk in February 2025 when she gathered wi…
The WeekFierceBiotech ↗
QuantumCell has licensed AlzeCure Pharma's Alzheimer's disease platform and lead asset for $12 million upfront…
The WeekBriefing
FDA approved Orca Bio’s Tregzi, the first allogeneic regulatory T cell therapy for blood cancer patients needi…
The WeekPharmaceutical Technology ↗
AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the Eur…
The WeekFiercePharma ↗
AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induc…
The WeekFierceBiotech ↗
Coming on the heels of a $130 million fundraising round just four months ago, bone-focused Angitia Biopharmace…
The WeekBriefing
Norwich Pharmaceuticals wins FDA approval for generic baloxavir marboxil, expanding affordable access to one-d…
The WeekBioPharma Dive ↗
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewher…
The WeekPharmaceutical Technology ↗
The trial of Fintepla in Dravet Syndrome and LGS was run by researchers at the Brno Epilepsy Centre in Czechia…
The WeekBioPharma Dive ↗
The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-p…
The WeekPharmaVoice ↗
Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the larges…
The WeekFiercePharma ↗
A Brukinsa regimen has delivered a large progression-free survival benefit in what BeOne Medicines called a "n…
The WeekFierceBiotech ↗
The FDA has delayed a decision on the approval of Praxis Precision Medicine's rare epilepsy prospect by three …
The WeekBriefing
The FDA’s June 2026 update again highlights brand drugs still lacking generic challengers, aiming to spur ANDA…
The WeekPharmaceutical Technology ↗
Talawar Therapeutics will use the funds to take its AD (eczema) bispecific, TALA-125, through to Phase IIb pro…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.